swing trader, thanks. you can imagine the problems with using an immunostimulatory medication such as Bavi on previously treated cancers since most of the treatments are net:net immunosuppressive...and permanently so. But this subject has been addressed ad nauseam in the past as an objection to any trial with Bavi-chemotherapy. So the "outperforming" chemo-only control group may or may not be assumed to be the same as the Bavi+chem group..depending on your point of view....which leaves us with a trial with no definite conclusions other than that Bavi seems to improve survival somewhat, but does not deal a convincing deathblow to advanced cancer when used alone or in combination with chemotherapy. This was a very poor choice for showcasing Bavi, but at the time it was the only open door we had for a clinical trial.
Market Data 
Markets 
AI
